Boehringer Ingelheim and Vanderbilt University have announced the expansion of their existing collaboration to develop novel anti-cancer compounds. The expanded research partnership will focus on the discovery and development of new chemical therapeutics targeting the pro-survival protein MCL1 as a potential therapy against MCL1 dependent cancers. This is the third collaboration between Boehringer Ingelheim and Vanderbilt University to pursue discoveries made in the laboratory of Stephen ...